Myeloid Differentiation Factor-2/LY96, a Potential Predictive Biomarker of Metastasis and Poor Outcomes in Prostate Cancer: Clinical Implications as a Potential Therapeutic Target

By
Laurisa Dohm
-
0
27
In vitro studies demonstrated that Myeloid differentiation factor-2 conferred invasiveness by activating MAPK and NF-kB signaling pathways and inducing epithelial–mesenchymal transition.
[Oncogene]
Full Article